RU2306925C2 - Method for treating periodontitis cases - Google Patents

Abstract

FIELD: medicine.

SUBSTANCE: method involves cutting out mucoperiosteal flap, making curettage and antiseptic treatment. Bone defect is filled with medical composition comprising Furacilin, aminocapronic acid, dimethylsulfoxide, glycerol, Chitosan, gelatin and water. Membrane cover is applied. The membrane has Furacilin, dimethylsulfoxide, acetic acid, glycerol, Aerosyl, Chitosan and water. The wound is covered with the mucoperiosteal flap and sutured.

EFFECT: enhanced effectiveness of treatment; prolonged hemostatic, antimicrobial and wound-healing action.

Description

The invention relates to medicine, in particular to surgical dentistry, and is intended for the treatment of periodontal diseases.

A known method of treating periodontal diseases by electrophoresis of medicinal substances (1, 2).

The disadvantage of these methods is the low effectiveness of the therapeutic effect and the short term of remission.

A known method of treating diseases of periodontal tissues by exposure to magnetic fields (3).

The disadvantage of this method is the lack of effectiveness of the therapeutic effect.

There is a method of surgical treatment of the disease by applying vagotil to the wound surface of the medicinal substance for 3-5 minutes (4).

The disadvantage of this method is the low effectiveness of the therapeutic effect and the short term of remission.

A known method for the surgical treatment of periodontitis by filling the defect with an allograft (5).

The disadvantage of this method is the possibility of postoperative complications.

There is a method of treating periodontitis by applying immunostimulating agents to the affected areas (6, 7).

The disadvantage of this method is the long duration of treatment with moderate and severe form of the disease.

There is also a known method for the treatment of periodontitis by cutting out a mucosal-cutaneous flap, curettage of a bone defect, antiseptic processing, filling with an autograft, applying a collagen membrane, laying a mucosal-cutaneous flap and suturing a wound (8).

The disadvantage of this method is the long duration of treatment and the possibility of developing postoperative complications.

The aim of the invention is to increase efficiency and reduce treatment time.

This goal is achieved by the fact that the filling of a bone defect is performed with a medicinal product, which includes (wt.%):

furatsilin 0.2-0.5 aminocaproic acid 0.5-5.0 dimethyl sulfoxide 2.0-5.0 glycerol 0.2-2.0 oxyl 1.0-3.0 chitosan 1.0-5.0 gelatin 9.0-15.0 purified water up to 100.0

and as a membrane using a membrane that includes (wt.%):

furatsilin 0.6-0.8 dimethyl sulfoxide 2.0-5.0 acetic acid 98% 1.0-4.0 aerosil 4.0-5.5 chitosan 1,5-5,0 purified water up to 100.0

Comparison of the proposed method with other known in the field of medicine showed its compliance with the criteria of the invention.

The proposed method is implemented as follows.

In sterile conditions, a drug is prepared to fill the bone cavity.

Under aseptic conditions, 1.5 (wt.%) Chitosan (TU 9289-003-49857769-2003 - "Chitosan crab" is placed in a 50 ml sterile container and 2% acetic acid (glacial acetic acid made from them - GOST 61-75) is poured ) room temperature in an amount of 50 ml was incubated for 2-3 hours until the dissolution of chitosan and the formation of a clear solution.The resulting solution was filtered.

In a separate sterile container, 5.0 medical gelatine (GF X st.309) is placed, 15-20 ml of purified water (FS 42-2619-97) is poured and left to swell for 30-40 minutes. Then add up to 50 ml the amount of purified water. Placed in a water bath and heated until dissolved.

In a sterile jar, furatsilina is weighed 0.05 dissolved in 0.3 dimethyl sulfoxide (DMSO) (VFS 42-1166-81), to the resulting solution of furatsilin add 0.2 g of oxyl (aerosil) and mix until a uniform lemon-yellow powder is obtained. 6.0 grams of the prepared chitosan solution are added to it, homogenized. 8.0 grams of gelatin solution are weighed and 0.1 grams of glycerol and 0.05 grams of aminocaproic acid are added. The resulting mass is homogenized at 40 ° C and poured into molds previously lubricated with sterile oil and cooled. Placed in the refrigerator for 15-20 minutes until solidification. After the specified time, the molds are opened, the obtained sticks are taken out and dried under aseptic conditions at room temperature to a residual moisture content of 1-2%.

The dried preparation is packaged in polyethylene and gas-permeable laminated paper BSG-40. Sterilized chemically (ethylene dioxide) at a temperature of 40 ± 5 ° C for 5 hours, and then subjected to degassing for 14 days.

A membrane is prepared as follows: separately, under aseptic conditions, furatsilin is dissolved in dimethyl sulfoxide (DMSO), and chitosan is dissolved in acetic acid. A solution of furatsilin in DMSO is adsorbed on Aerosil and mixed with a solution of chitosan until a homogeneous mass is obtained. It is kept in an open container for 30 minutes to remove air bubbles and poured under aseptic conditions onto sterile glass substrates with a thickness of not more than 5 mm. Dried at room temperature to a residual moisture content of 2%. After drying, the resulting plates with a thickness of 1 mm are dispensed onto membranes of various sizes.

The dried membranes are packaged in polyethylene or glass vials and sterilized by radiation sterilization (Co ⁶⁰ ).

Prepare the patient for surgery. According to the well-known technique, mucosal-subcutaneous flap is cut out, curettage, aseptic processing is performed, the bone defect is filled with the prepared medicinal product, the membrane prepared in advance is applied, the mucoperiostate flap is laid and the surgical wound is sutured.

The drug and the membrane have a prolonged cleansing hemostatic, antimicrobial, wound healing and anti-inflammatory effects.

The positive effect of using the proposed method is expressed in increasing efficiency and reducing treatment time.

The proposed method is possible and appropriate to use for the treatment of periodontitis in the dental units of medical institutions.

INFORMATION SOURCES

1. Auth. testimonial. USSR No. 1392674, Cl. A61K 31/60, 1979.

2. Auth. testimonial. USSR No. 1041116, Cl. A61K 6/00, 1983.

3. Auth. testimonial. USSR No. 1219087, Cl. A61K 31/60, 1986.

4. Auth. testimonial. USSR No. 1409236, Cl. A61B 17/00, 1988.

5. Auth. testimonial. USSR No. 1572536, Cl. A61B 17/00, 1990.

6. Auth. testimonial. USSR No. 1514377, Cl. A61K 35/14, 1987.

7. Dereyko L.V. Dentistry, No. 1, 1987. S. 32-34.

8. Bezrukov V.M. and other surgical dentistry. M., 2002. P.76.

Claims (1)

A method for the treatment of periodontitis by cutting out a mucosal-periosteal flap, curettage, antiseptic treatment, filling a bone defect, applying a membrane, laying a mucous-periosteal flap and suturing a wound, characterized in that the filling of a bone defect is performed with a medicinal product, including wt.%: furatsilin 0.2-0.5 aminocaproic acid 0.5-5.0 dimethyl sulfoxide 2.0-5.0 glycerol 0.2-2.0 oxyl 1.0-3.0 chitosan 1.0-5.0 gelatin 9.0-15.0 purified water up to 100.0 and as a membrane using a membrane, including, wt.%: furatsilin 0.6-0.8 dimethyl sulfoxide 2.0-5.0 acetic acid 98% 1.0-4.0 aerosil 4.0-5.5 chitosan 1,5-5,0 purified water up to 100.0